DailyIQ
Last updatedUpdating…

INCY·Incyte Corporation

$111.57
+2.95 (+2.72%)
After Hours
High
$112.06
Open
$108.61
Market Cap
22.01B
52W High
$133.41
Low
$107.83
P. Close
$111.57
P/E
13.65
52W Low
$83.00
Fwd P/E
12.49
DailyIQ Est.
$133.16
Inst. Ownership
38.2%
Short Interest
4.93%
Days to Cover
6.1
Technical Score (1D)
86
BULLISH
News Sentiment
58
BULLISH
On Oct 13, HC Wainwright & Co. reaffirmed its Buy rating for Incyte and kept the $152 price target unchanged. The firm cited Incyte’s robust pipeline and recent clinical milestones as key drivers for the upgrade. The recommendation signals confidence in the company’s growth prospects within the current market context. No material upside or significant change in guidance was indicated by the rating. The update reflects a positive outlook for the stock based on the cited factors.
LOW TARGET
$86 -22.9%
2 analysts
MEAN TARGET
$130 +16.1%
23 analysts
HIGH TARGET
$157 +40.7%
12 analysts
PRICE RANGE
$86.00 - $157.00
SB / B / H / S / SS
8/10/17/1/1
DAILYIQ EST.
$133.16 (+19.4%)
Sector
Healthcare
Industry
Biotechnology
Exchange
NMS
Country
United States
Website
Symbol
INCY
Description
Incyte Corporation is a biopharmaceutical firm focused on discovering, developing, and commercializing innovative therapies for various medical conditions across the United States, Europe, Canada, and Japan. The company's marketed products include treatments for myelofibrosis, lymphoma, biliary tract cancer, chronic myeloid leukemia, Merkel cell carcinoma, atopic dermatitis, and chronic graft-versus-host disease. Incyte also has a robust pipeline of clinical-stage candidates targeting diseases such as ovarian cancer, solid tumors, hidradenitis suppurativa, vitiligo, and systemic immune disorders. Their products are distributed through specialty and retail pharmacies, hospital pharmacies, and wholesale channels. Originally incorporated in 1991 and headquartered in Wilmington, Delaware, Incyte leverages its research and development capabilities to address significant unmet medical needs.
Bought (1Y)
0 shares
$0
Sold (1Y)
273,281 shares
$31.0M
Heeson LeeEVP, Head of Incyte Intl
Tax Withholding463 shares2026-10-01
HARRIGAN EDMUND-
Award/Grant206 shares2026-09-30
BAKER BROS. ADVISORS LP-
Award/Grant322 shares2026-09-30
Clancy Paul J-
Award/Grant203 shares2026-09-30
Gardner David HEVP, Chief Strategy Officer
Tax Withholding920 shares2026-09-22
89/ 100
Strong bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
25.0%
Revenue CAGR
48.4%
Current Ratio
3.32x
Debt / Equity
3.83x
Return on Equity
24.9%
Earnings Summary
Incyte Corporation is a biopharmaceutical company focused on developing therapies for myelofibrosis, lymphoma, and other conditions, with a robust pipeline targeting solid tumors and immune disorders. In the biotechnology industry, Incyte has consistently delivered earnings that exceed analyst expectations, as evidenced by Q4 2024 EPS of $1.43 versus an estimate of $1.55 and Q1 2025 EPS of $1.16 beating the $1.03 estimate, while revenue grew from $1.179B to $1.053B. The company’s recent quarters show a strong upward trend in both revenue and EPS, with Q3 2025 EPS of $2.26 surpassing the $1.64 estimate and revenue reaching $1.366B. Historically, Incyte has maintained a pattern of beating earnings estimates and achieving revenue growth, even when facing competitive pressures. Recent news indicates that HC Wainwright & Co. reaffirmed a Buy rating and maintained a $152 target, reflecting confidence in Incyte’s pipeline and recent clinical milestones. Analysts also forecast a loss for Q3 2026, signaling a short‑term setback; however, the company’s track record suggests resilience.

EPS

EstBeatMiss
$-4.72$-2.51$-0.31$1.90$4.11Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$-3.70 - -
Q2'26$2.15$3.09+43.9%
Q1'26$1.34$1.81+35.1%
Q4'25$1.57$1.80+14.8%
Q3'25$1.64$2.26+38.0%
Q2'25$1.47$1.57+6.6%

Revenue

EstBeatMiss
$1.1B$1.3B$1.4B$1.6B$1.7BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.5B - -
Q2'26$1.5B$1.7B+11.4%
Q1'26$1.2B$1.3B+5.1%
Q4'25$1.3B$1.5B+20.5%
Q3'25 - $1.4B -
Q2'25 - $1.2B -

Market Data

INCY Stock Snapshot

BULLISH86/100
$111.57+$0.00 (0.0%)
Market cap
22.01B
P/E ratio
13.7
Day range
$107.83 – $112.06
News sentiment
58/100 · Neutral
Analyst target
$129.54 (+16.1%)
Consensus
Hold · 37 analysts
52-week range+34.4% off low · -16.4% from high
$83.00$133.41
Price $111.57 DailyIQ Est. $133.16

The signal on INCY is bullish: price action is confirming the underlying trend, not fighting it. In Healthcare, names this size usually take direction from sector flows before company-level news.

Behaviour On Record

What INCY's own history says about today's numbers

Realized volatility (21d)
29.8% 33rd pct
Below its peak
-28.3%
vs 200-day average
+1.4%
Up days (1y)
50%

Incyte Corporation is currently running 29.8% annualised volatility over the last 21 sessions. Measured against INCY's own 13 years of daily returns rather than a market-wide average, that is the 33rd percentile — on the quiet side for this stock, against a typical reading of 34.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

INCY is trading -28.3% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -32.2%, and the deepest was -42.6% in 2018. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +1.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 49th percentile — close to the gap it normally carries. Over the past year INCY closed higher on 50% of sessions, and it is currently 2 sessions into a falling streak.

On October specifically: over 13 years of records, INCY finished the month higher 6 of 13 times, with a median return of -0.3% and an average of +4.1%. Its strongest month historically has been October at +4.1% on average, its weakest September at -4.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: INCY has opened more than 2% away from the prior close in 219 of 3,267 sessions (6.7% of the time), with the largest gaps running +10.7% and -19.3%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, INCY moved an average of 1.6% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.6% and a largest of -2.2%.

All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against INCY's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of INCY's sector?

Incyte Corporation sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Biotechnology industry group, INCY ranks 9th of 15 tracked industries, improving.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82
Industry rank
#9 of 15

Options Market

What is the options market pricing for INCY?

CallsPuts

For Incyte Corporation's nearest expiry (2026-10-16, 2 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 1.30), with at-the-money implied volatility around 62.3%. The options market is pricing roughly a ±4.9% move by that expiry — a range of about $105.81–$116.66.

Put/call ratio (2026-10-16)
1.30
ATM implied volatility
62.3%
Total open interest
2,267
Expected move by 2026-10-16
±4.9% ($105.81–$116.66)

Analyst Rating Changes

Are analysts turning bullish or bearish on INCY?

Truist Securities most recently reiterated its rating on Incyte Corporation to Hold on Oct 14, 2026 with a price target of $115 (from $105). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Truist Securities — Hold
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 14, 2026Truist SecuritiesMaintainedHold$105 → $115
Oct 13, 2026HC Wainwright & Co.ReiteratedBuy$152
Oct 8, 2026RBC CapitalMaintainedSector Perform$109 → $114
Oct 5, 2026StifelMaintainedBuy$145 → $157
Oct 1, 2026Wells FargoMaintainedEqual-Weight$116 → $128
Sep 28, 2026JP MorganMaintainedNeutral$120 → $123
Sep 28, 2026HC Wainwright & Co.MaintainedBuy$150 → $152
Sep 22, 2026RBC CapitalReiteratedSector Perform$109
Aug 20, 2026Canaccord GenuityInitiatedBuy$152
Aug 20, 2026HC Wainwright & Co.ReiteratedBuy$150
Aug 17, 2026Piper SandlerMaintainedOverweight$110 → $130
Aug 4, 2026MizuhoMaintainedOutperform$121 → $137

Peers & ETF holders

INCY peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

58/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
On October 13, HC Wainwright & Co. reaffirmed its Buy rating for Incyte (NASDAQ:INCY) and maintained a $152 price target. The firm cited the company’s robust pipeline and recent clinical milestones as key drivers for the upgrade. The recommendation signals confidence in Incyte’s growth prospects but does not indicate a material upside or significant change in guidance. The rating reflects a positive outlook for the stock within the current market context.
What did this article say?
Incyte announced that its third‑quarter earnings would be released shortly, with analysts projecting a steep triple‑digit drop in net income compared to the same period last year. The forecast signals a significant deterioration in profitability, likely driven by higher operating costs and lower revenue growth. The market had already priced in a modest decline, but the magnitude of the projected loss exceeds prior expectations, raising concerns about the company’s financial health. This development may prompt a downgrade or a reassessment of future guidance. The announcement underscores the need for investors to monitor the company’s cost‑control measures and pipeline performance.
What did this article say?
Incyte Corporation scheduled its third‑quarter 2026 earnings announcement for October 8, 2026. The company will report financial results for the period ending September 30, 2026. No guidance or performance updates were provided in the announcement. The release is a routine quarterly update with no immediate impact on the company’s outlook.
What did this article say?
RBC Capital analyst Brian Abrahams maintained a Sector Perform rating for Incyte (NASDAQ:INCY) and increased the price target from $109 to $114. The upgrade reflected confidence in the company’s pipeline and recent clinical data. The move signals a positive outlook for the firm’s valuation and growth prospects.
What did this article say?
Incyte (NASDAQ:INCY) achieved an average annual return of 14.45% over the past 15 years, outperforming the broader market by 1.22% on an annualized basis. The company’s market capitalization stands at $22.70 billion. This historical performance highlights the company’s consistent growth trajectory and investor appeal.
What did this article say?
Stifel increased its price target for Incyte (INCY) from $145 to $157 while keeping a buy rating. The adjustment reflects a more optimistic view of the company’s future earnings potential. The new target aligns with the average analyst consensus of $130.78 and an overweight rating. This move signals confidence in Incyte’s growth prospects without indicating a major strategic shift.
What did this article say?
Stifel analyst Stephen Willey upgraded Incyte to a Buy rating and increased the price target from $145 to $157. The upgrade reflects confidence in the company’s pipeline and recent financial performance. The new target suggests a bullish outlook for the stock, indicating potential upside for investors.
What did this article say?
The Q2 earnings season concluded with a review of biotechnology firms, including Incyte (NASDAQ:INCY). Incyte’s results were highlighted among the sector’s performances, offering investors a snapshot of its financial health and market positioning. The coverage provided a concise comparison of Incyte’s earnings against peers, underscoring its relative standing within the industry. No significant guidance changes or material events were noted, suggesting a steady outlook for the company.
What did this article say?
Incyte (NASDAQ:INCY) has delivered an average annual return of 17.52% over the past two decades, outperforming the broader market by 8.48% on an annualized basis. The company’s market capitalization stands at $23.82 billion. The historical performance highlights Incyte’s long‑term value creation, though it does not reflect any recent catalysts or forward guidance.

Technical Analysis

Real-time indicators across multiple timeframes

86
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $8.42B combined position · 16 adding, 9 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▼ Sell18,032,7188.90%$2.04B2026-08-07
Vanguard Group Inc▼ Sell19,911,4349.83%$1.97B2026-01-29
AQR Capital Management LLC▼ Sell5,320,9012.63%$603.18M2026-08-14
Geode Capital Management, LLC▲ Buy4,750,7352.34%$536.52M2026-08-12
Invesco Ltd.▲ Buy4,080,4612.01%$462.56M2026-08-14
Wellington Management Group LLP▲ Buy3,575,5211.76%$405.32M2026-08-14
Renaissance Technologies LLC▼ Sell3,512,1321.73%$398.14M2026-08-13
Morgan Stanley▲ Buy2,948,3641.46%$334.23M2026-08-13
Goldman Sachs Group Inc▼ Sell2,305,7821.14%$261.38M2026-08-14
Two Sigma Investments, LP▲ Buy2,003,5590.99%$227.12M2026-08-14
Northern Trust Corp▼ Sell1,761,9660.87%$199.74M2026-08-13
FMR LLC (Fidelity)▲ Buy1,381,7730.68%$156.64M2026-08-13
Marshall Wace, LLP▲ Buy1,310,1540.65%$148.52M2026-08-13
Norges Bank▼ Sell1,119,1070.55%$126.86M2026-08-12
Man Group plc▲ Buy952,9410.47%$108.03M2026-08-14
JPMorgan Chase & Co▲ Buy761,6900.38%$87.34M2026-08-12
Gotham Asset Management, LLC▲ Buy719,5450.36%$81.57M2026-08-14
Bank of America Corp▼ Sell676,1910.33%$76.65M2026-08-14
Citigroup Inc▲ Buy586,4310.29%$66.48M2026-08-03
Wells Fargo & Company▲ Buy255,0640.13%$28.91M2026-08-14
Winton Group Ltd▲ Buy254,4080.13%$28.84M2026-08-07
Prudential Financial Inc▼ Sell191,3120.09%$21.69M2026-08-12
Bridgewater Associates, LP▲ Buy168,2530.08%$19.07M2026-08-14
AllianceBernstein L.P.▲ Buy201,2090.10%$18.94M2026-08-14
Citadel Advisors LLC▲ Buy143,5090.07%$16.27M2026-09-02
Q2 2026 flow:3.18M sh bought ($359.96M)2.25M sh sold ($255.35M)net +922.8K sh (+$104.62M)
Congressional Trading Activity
3 disclosed trades · ~$24.0K est. traded value · 1 buys, 2 sells
MemberChamberStateTypeAmountTradedFiled
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-05-152025-05-31
Shelley Moore CapitoSenateWV▼ Sell$1K - $15K2018-11-122018-12-08
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2017-09-082017-10-06